Loading
A head-to-head comparison of three blood compartments for a prostate cancer resistance RNA, in which circulating tumour cells beat cell-free and vesicle RNA.
AR and AR-V7 RNA were detectable in circulating tumour cells, circulating tumour RNA and exosomes, and AR-V7 detection from circulating tumour cells showed higher sensitivity than detection from cell-free RNA and exosomes.
Reading a phenotype from cell-free RNA can be less sensitive than from whole tumour cells in blood.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares AR-V7 splice variant, Metastatic castration-resistant prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/